New research collaboration to study RNA-binding proteins for the creation of new therapeutic target candidates
Posted: 20 April 2015 | Victoria White
Takeda, Keio University and Niigata University are to collaborate to research disease-related RNA-binding proteins, possibly leading to new treatments…
Just days after announcing their collaboration with CiRA on iPS cell research, Takeda has entered in to another collaborative research agreement with Keio University School of Medicine and Niigata University regarding the search for and functional analysis of disease-related RNA-binding proteins.
This may lead to treatments in the areas such as CNS and oncology.
This collaboration is scheduled to last three years, with Professor Hideyuki Okano of the Physiology Laboratory at Keio University School of Medicine directing the overall research, with Associate Professor Masato Yano from Niigata University participating as well.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Research collaboration will focus on the systematic and comprehensive study of RNA-binding proteins
The relationship between disease pathology and RNA-binding proteins has gradually become clearer in recent years, and a diseases’ onset and progression is now thought to be linked to abnormalities in RNA-binding proteins. This research collaboration will focus on the systematic and comprehensive study of RNA-binding proteins, with the aim of creating new therapeutic target candidates and game-changing technologies for drug discovery.
“We hope to produce innovative results for drug discovery through the uniting of our research on RNA-binding proteins with Takeda’s science technology platform,” said Professor Hideyuki Okano, Keio University School of Medicine.
By collaborating with both universities, Takeda hopes to create ground-breaking medicine
“I am very excited to welcome Professor Okano, who is one of the world’s leading researchers engaged in RNA-binding proteins, into this important Initiative,” said Tetsuyuki Maruyama, General Manager of the Pharmaceutical Research Division. “By collaboration with both universities, Takeda hopes to create the new ground-breaking medicine that patients are waiting for.”
For more information about Takeda Pharmaceutical Company Ltd., please visit www.takeda.com.
Related topics
Drug Discovery, RNAs
